P53 Polymorphism and Risk of Cervical Cancer

Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.

P53 Polymorphism and Risk of Cervical Cancer

Nature (12/10/98) Vol. 396, No. 6711, P. 530
Helland, Aslaug; Josefsson, Agnetha; Hildensheim, Allan; et al.

Three separate groups of researchers respond to findings recently reported in Nature by Alan Storey and colleagues indicating that a polymorphism in the p53 gene at codon-72 represents a significant risk factor for cancers associated with human papillomavirus. In letters to the journal, all three research groups report that people homozygous for arganine substitutions at the position were not at higher risk for the cancers, as Storey et al. reported. One group, from the National Cancer Institute and elsewhere, even found that the polymorphism was associated with a decreased risk of neoplasia. All of the groups had larger study sizes but were conducted among different populations than the original study by Storey. In response, Storey, of the Imperial Cancer Research Fund in London, and others state that sample sizes, study population, screening techniques, and control choice all could be responsible for the differences in findings. They state that "it is crucial that investigations should be extended to different populations, and we are encouraged that such studies are underway." The authors are now investigating the risk rates among populations with a higher percentage of the proline allele; findings thus far support their original results.

981217
AD982375

Copyright © 1998 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.